ANDREWS RONALD ASBURY 4

What Happened
Ronald Asbury Andrews, a director of PLUS THERAPEUTICS, had 922 restricted stock units (RSUs convertibles to common shares) vest and convert into 922 shares on July 1, 2026. The Form 4 reports the conversion/exercise of a derivative instrument at $0.00 per share (acquired) and the concomitant disposition of the derivative (also $0.00) — total cash exchanged reported: $0. This is a vesting/conversion event (award settling into shares), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-01; reported exercise/conversion price: $0.00 per share.
• Shares acquired (from RSU conversion): 922 shares.
• Filing date / Period of report: 2026-07-01 (filed same day).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — each RSU converts to one share of common stock; F2 — this RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026.
• No tax withholding, sale, or 10b5‑1 plan is reported in this filing.

Context
This was a routine RSU vesting/conversion (derivative-to-share settlement). The filing shows both the acquisition of shares and the corresponding disposition of the underlying derivative instrument — a common way Form 4s report RSU vesting. Because no open-market purchase or sale occurred, this transaction is informational about compensation vesting rather than a directional insider bet on the stock.